Physician profile
Kyle Robert Randall
NPI 1154396364
$1,064.27
in general payments reported to CMS, 2019-2025
22 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $15.05 · 2022: $19.13 · 2023: $626 · 2024: $121 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $523 · Food and Beverage: $355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $522.97 |
| Food and Beverage | $355.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| True North Surgical INC | $522.97 | 2023 | |
| Amgen INC. | $61.79 | 2024-2025 | Krystexxa |
| Axsome Therapeutics, INC. | $53.26 | 2024-2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $40.45 | 2023 | |
| Fidia Pharma USA INC. | $36.43 | 2019 | |
| Merck Sharp & Dohme LLC | $34.92 | 2023-2024 | Vaxneuvance, Gardasil 9, M-M-R II |
| Endo Pharmaceuticals INC. | $33.93 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $30.46 | 2019 | |
| Tactile Systems Technology INC | $29.33 | 2025 | Flexitouch Plus, Nimbl |
| Abbvie INC. | $23.46 | 2025 | |
| Exact Sciences Corporation | $19.82 | 2025 | The Cologuard Plus Collection Kit |
| Smith+Nephew, INC. | $19.65 | 2024 | Collagenase Santyl |
| Zimmer Biomet Holdings, INC. | $19.13 | 2022 | |
| Pacira Therapeutics, INC. | $19.06 | 2019 | |
| Stryker Corporation | $17.36 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $16.69 | 2019 | |
| Novo Nordisk INC | $16.08 | 2023 | |
| Horizon Therapeutics Plc | $15.20 | 2023 | Krystexxa |
| Becton, Dickinson and Company | $14.45 | 2024 | Bd Onclarity |
| Xeris Pharmaceuticals, INC. | $13.65 | 2024 | Gvoke Hypopen |
| Spinesmith Holdings, LLC | $13.09 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.09 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Randall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.